Hikma FDA Tuesday, September 8, 2020 +0.60 Positive

FDA Approves FOSAPREPITANT DIMEGLUMINE — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. announced the approval of its generic fosaprepitant dimeglumine intravenous injection by the FDA, a motion sickness antiemetic expected to generate significant market revenue. This ANDA approval allows for a late entrant's expansion into the U.S. market following a patent settlement, directly challenging the biologic Kalypso as successor products from other large manufacturers continue to proliferate.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed